Heterocyclic amides of formula (1) 1
wherein:
R.sup.1 is independently selected from, for example, C.sub.1-6alkyl,
C.sub.5-7cycloalkyl, C.sub.5-7cycloalkylC.sub.1-3alkyl, C.sub.1-6alkoxy,
C.sub.5-7cycloalkoxy, C.sub.5-7cycloalkylC.sub.1-3alkoxy, heterocyclyl,
heterocyclylC.sub.1-3alkyl, heterocyclyloxy or heterocyclylC.sub.1-3alkox-
y,
R.sup.2 is phenyl or heteroaryl;
R.sup.3 is independently selected from hydrogen, halo, nitro, cyano,
hydroxy, carboxy, carbamoyl, C.sub.1-4alkyl, C.sub.2-4alkenyl,
C.sub.2-4alkyl, C.sub.1-4alkoxy, C.sub.1-4alkanoyl, fluoromethyl,
difluoromethyl trifluoromethyl and trifluoromethoxy;
or a pharmaceutically acceptable salt or pro-drug thereof; possess
glycogen phosphorylase inhibitory activity and accordingly have value in
the treatment of disease states associated with increased glycogen
phosphorylase activity. Processes for the manufacture of said
heterocyclic amide derivatives and pharmaceutical compositions containing
them are described.
